76.48
price up icon8.69%   6.3238
 
loading
Precedente Chiudi:
$70.16
Aprire:
$72
Volume 24 ore:
2.20M
Relative Volume:
1.21
Capitalizzazione di mercato:
$14.80B
Reddito:
$4.41B
Utile/perdita netta:
$21.27M
Rapporto P/E:
239.01
EPS:
0.32
Flusso di cassa netto:
$288.81M
1 W Prestazione:
+10.68%
1M Prestazione:
+11.54%
6M Prestazione:
+3.44%
1 anno Prestazione:
+11.18%
Intervallo 1D:
Value
$71.00
$76.65
Intervallo di 1 settimana:
Value
$69.69
$76.65
Portata 52W:
Value
$53.56
$83.95

Incyte Corp Stock (INCY) Company Profile

Name
Nome
Incyte Corp
Name
Telefono
(302) 498-6700
Name
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
Dipendente
2,617
Name
Cinguettio
@Incyte
Name
Prossima data di guadagno
2025-02-10
Name
Ultimi documenti SEC
Name
INCY's Discussions on Twitter

Confronta INCY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
INCY
Incyte Corp
76.46 13.59B 4.41B 21.27M 288.81M 0.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
467.58 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
557.24 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.76 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
596.29 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
305.38 31.54B 3.81B -644.79M -669.77M -6.24

Incyte Corp Stock (INCY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-16 Aggiornamento Stifel Hold → Buy
2025-03-18 Downgrade Guggenheim Buy → Neutral
2025-03-18 Downgrade William Blair Outperform → Mkt Perform
2024-12-17 Iniziato UBS Neutral
2024-10-29 Aggiornamento BofA Securities Neutral → Buy
2024-10-01 Iniziato Wolfe Research Outperform
2024-09-18 Downgrade Truist Buy → Hold
2024-07-02 Downgrade BMO Capital Markets Market Perform → Underperform
2024-05-23 Iniziato Deutsche Bank Hold
2024-04-23 Iniziato Cantor Fitzgerald Neutral
2024-02-23 Iniziato Jefferies Buy
2024-02-14 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2023-12-13 Aggiornamento Leerink Partners Market Perform → Outperform
2023-12-04 Aggiornamento Guggenheim Neutral → Buy
2023-11-21 Downgrade Goldman Buy → Neutral
2023-07-25 Iniziato Citigroup Buy
2023-05-04 Downgrade BofA Securities Buy → Neutral
2023-04-10 Downgrade RBC Capital Mkts Outperform → Sector Perform
2023-03-24 Aggiornamento SVB Securities Underperform → Market Perform
2023-01-31 Iniziato Piper Sandler Overweight
2022-08-03 Downgrade Evercore ISI Outperform → In-line
2022-08-03 Downgrade Guggenheim Buy → Neutral
2022-07-28 Iniziato Wells Fargo Equal Weight
2022-02-09 Downgrade SVB Leerink Mkt Perform → Underperform
2022-01-18 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2021-11-19 Iniziato BMO Capital Markets Market Perform
2021-07-20 Aggiornamento The Benchmark Company Hold → Buy
2021-02-10 Downgrade SVB Leerink Mkt Perform → Underperform
2021-01-07 Iniziato Truist Buy
2021-01-04 Aggiornamento Guggenheim Neutral → Buy
2020-06-16 Iniziato The Benchmark Company Hold
2020-05-06 Downgrade JP Morgan Overweight → Neutral
2020-04-29 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-04-01 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2020-03-24 Ripresa William Blair Outperform
2020-03-13 Aggiornamento BofA/Merrill Neutral → Buy
2020-02-04 Ripresa BofA/Merrill Neutral
2020-01-03 Reiterato BMO Capital Markets Market Perform
2020-01-03 Downgrade Mizuho Buy → Neutral
2020-01-02 Downgrade Guggenheim Buy → Neutral
2019-10-03 Iniziato Mizuho Buy
2019-09-12 Iniziato BMO Capital Markets Market Perform
2019-09-05 Aggiornamento JMP Securities Mkt Perform → Mkt Outperform
2019-09-05 Ripresa Morgan Stanley Equal-Weight
2019-09-05 Aggiornamento Oppenheimer Perform → Outperform
2019-05-21 Iniziato Credit Suisse Neutral
2019-05-03 Downgrade Barclays Overweight → Equal Weight
2019-04-11 Iniziato Stifel Hold
2019-04-03 Downgrade RBC Capital Mkts Outperform → Sector Perform
2019-01-24 Aggiornamento William Blair Mkt Perform → Outperform
Mostra tutto

Incyte Corp Borsa (INCY) Ultime notizie

pulisher
11:13 AM

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand - Benzinga

11:13 AM
pulisher
10:35 AM

Incyte earnings beat by $0.17, revenue fell short of estimates - Investing.com Canada

10:35 AM
pulisher
09:57 AM

Earnings call transcript: Incyte Q2 2025 reveals revenue miss, stock gains - Investing.com

09:57 AM
pulisher
09:39 AM

Incyte lifts annual sales forecast for blood cancer drug after solid quarter - 1470 & 100.3 WMBD

09:39 AM
pulisher
08:39 AM

Incyte Q2 Results Top Estimates - Nasdaq

08:39 AM
pulisher
08:26 AM

Incyte Q2 2025 slides: revenue up 16%, raises guidance on strong product performance - Investing.com

08:26 AM
pulisher
08:01 AM

Incyte Corp reports results for the quarter ended June 30Earnings Summary - TradingView

08:01 AM
pulisher
07:52 AM

Incyte misses Q2 earnings estimates, raises Jakafi guidance By Investing.com - Investing.com Canada

07:52 AM
pulisher
07:32 AM

Incyte: Q2 Earnings Snapshot - San Antonio Express-News

07:32 AM
pulisher
07:32 AM

Incyte Corp Q2 2025 Earnings: EPS of $2.04 and Revenue of $1.216 Billion Surpass Estimates - GuruFocus

07:32 AM
pulisher
07:15 AM

Incyte Reports 2025 Second Quarter Financial Results - TradingView

07:15 AM
pulisher
07:00 AM

Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs - Business Wire

07:00 AM
pulisher
Jul 28, 2025

Incyte (INCY) Anticipates Q2 Earnings with Positive Expectations - GuruFocus

Jul 28, 2025
pulisher
Jul 27, 2025

How volatile is Incyte Corporation stock compared to the marketRealize exceptional returns through smart trading - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Does Incyte Corporation stock perform well during market downturnsNavigate market shifts with confidence - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 25, 2025

Earnings Preview: Incyte to Report Financial Results Pre-market on July 29 - 富途牛牛

Jul 25, 2025
pulisher
Jul 25, 2025

Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects - MSN

Jul 25, 2025
pulisher
Jul 24, 2025

Incyte to present initial data on cancer therapies at ESMO Congress - Investing.com

Jul 24, 2025
pulisher
Jul 24, 2025

Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025 - Business Wire

Jul 24, 2025
pulisher
Jul 24, 2025

Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards? - Nasdaq

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Incyte Corporation stockFree Buy/Sell Signal Notifications - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Incyte Corporation stock priceHigh-impact stock picks - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Incyte (INCY) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Jul 22, 2025
pulisher
Jul 19, 2025

Is Incyte Corporation a good long term investmentTremendous return rates - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 17, 2025

Is BrightSpring Health Services, Inc. (BTSG) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Jul 17, 2025
pulisher
Jul 16, 2025

Incyte EVP Flannelly sells $83k in shares - Investing.com

Jul 16, 2025
pulisher
Jul 16, 2025

Incyte EVP Flannelly sells $83k in shares By Investing.com - Investing.com UK

Jul 16, 2025
pulisher
Jul 16, 2025

Sun Pharma launches Leqselvi in US; settles litigation with Incyte Corp - MSN

Jul 16, 2025
pulisher
Jul 15, 2025

Incyte Announces Q2 2025 Financial Results Call and Webcast Details - MyChesCo

Jul 15, 2025
pulisher
Jul 15, 2025

Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN

Jul 15, 2025
pulisher
Jul 15, 2025

Incyte stock price target raised to $62 from $61 at UBS on sales outlook - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Sun Pharma Shares Climb 3%, Leqselvi Settlement - Rediff

Jul 15, 2025
pulisher
Jul 14, 2025

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S. - The Hindu

Jul 14, 2025
pulisher
Jul 14, 2025

Sun Pharma launches Leqselvi in US after patent settlement with Incyte Corp - Business Standard

Jul 14, 2025
pulisher
Jul 14, 2025

India's Sun Pharma launches hair loss drug Leqselvi in US after patent settlement - Reuters

Jul 14, 2025
pulisher
Jul 14, 2025

Sun Pharma’s baldness drug Leqselvi debuts in US market after patent dispute settled - The Economic Times

Jul 14, 2025
pulisher
Jul 14, 2025

Sun Pharma settles litigation with Incyte Corp - theweek.in

Jul 14, 2025
pulisher
Jul 14, 2025

Sun Pharma Settles Incyte Corp Litigation - Rediff

Jul 14, 2025
pulisher
Jul 14, 2025

India's Sun Pharma launches anti-baldness drug Leqselvi in US - MarketScreener

Jul 14, 2025
pulisher
Jul 11, 2025

Incyte discloses new bicyclooctane KRAS inhibitors - BioWorld MedTech

Jul 11, 2025
pulisher
Jul 10, 2025

Anal Cancer Market Research Report 2025-2035 with Competitive Profiles of Incyte, BioMimetix, Bristol Myers Squibb, and AstraZeneca - Yahoo Finance

Jul 10, 2025
pulisher
Jul 10, 2025

Incyte’s Q2 2025 Earnings: What To Expect - Barchart.com

Jul 10, 2025
pulisher
Jul 10, 2025

Incyte to Report Second Quarter Financial Results - Business Wire

Jul 10, 2025
pulisher
Jul 09, 2025

William Blair Maintains ‘Hold’ Rating on Incyte Corporation (INCY), Citing Future Revenue Uncertainties - Insider Monkey

Jul 09, 2025
pulisher
Jul 06, 2025

Incyte Announces Equity Awards for New CEO Bill Meury with Performance-Based Incentives - MyChesCo

Jul 06, 2025
pulisher
Jul 03, 2025

Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock? - MSN

Jul 03, 2025
pulisher
Jul 03, 2025

Incyte: New CEO Brings A New Possible Outcome (NASDAQ:INCY) - Seeking Alpha

Jul 03, 2025
pulisher
Jul 02, 2025

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jul 02, 2025

Incyte Corp Azioni (INCY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$37.37
price up icon 0.82%
$104.10
price up icon 2.27%
$26.82
price down icon 2.13%
$110.33
price down icon 2.19%
biotechnology ONC
$305.38
price up icon 3.60%
Capitalizzazione:     |  Volume (24 ore):